Short Bowel Syndrome Epidemiology Forecast 2025-2034

Short bowel syndrome is a rare condition with global prevalence ranging 0.12-2.74 per 100,000, highest in the US and Poland, predominantly affecting adults, especially females, and requiring specialized nutritional management. According to short bowel syndrome epidemiology forecast by Expert Market Research, the condition is more prevalent in females as compared to males.

Short Bowel Syndrome Epidemiology Forecast Report Coverage

Expert Market Research's “Short Bowel Syndrome Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of short bowel syndrome. It projects the future incidence and prevalence rates of short bowel syndrome cases across various populations. The study covers age, gender, and type as major determinants of the short bowel syndrome population. The report highlights patterns in the prevalence of short bowel syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on short bowel syndrome epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Short Bowel Syndrome Understanding: Disease Overview

Short bowel syndrome (SBS) is a rare malabsorptive disorder resulting from extensive surgical resection or congenital absence of the small intestine. The condition impairs nutrient, fluid, and electrolyte absorption, leading to malnutrition, dehydration, and weight loss. Severity depends on the remaining bowel length, location of resection, and presence of the colon. Common causes include Crohn’s disease, mesenteric ischemia, trauma, or congenital defects. SBS can lead to chronic intestinal failure requiring long-term nutritional support, significantly affecting quality of life and increasing morbidity and healthcare burden globally.

Short Bowel Syndrome Epidemiology Perspective

The short bowel syndrome epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the short bowel syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for short bowel syndrome and their trends. The short bowel syndrome detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• A 2024 study estimated that the prevalence of diagnosed SBS-associated intestinal failure (SBS-IF) in adults ranged from 0.12 to 2.74 per 100,000 individuals.
• The estimated prevalence in children was between 0.09 and 1.67 per 100,000, with higher rates in North America and Europe.
• A study involving 68 short bowel syndrome patients reported that 79% were female, indicating a higher prevalence in women.

Country-wise Short Bowel Syndrome Epidemiology Segment

The short bowel syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Short bowel syndrome (SBS) is a rare condition with varying prevalence across countries. The highest prevalence is reported in the United States (2.74 per 100,000), reflecting scope of improvement in healthcare infrastructure, reporting, and surgical practices. SBS affects both adults and children, with adult females representing a higher proportion of cases. Regional variations highlight the importance of early diagnosis, specialized care, and access to nutritional support to manage chronic intestinal failure associated with short bowel syndrome.

Short Bowel Syndrome: Treatment Overview

The management of short bowel syndrome focuses on restoring nutrition, promoting intestinal adaptation, and preventing complications. Treatment includes oral or enteral nutrition, parenteral nutrition for severe malabsorption, and pharmacologic therapies such as GLP-2 analogs to enhance intestinal absorption. Surgical interventions, including bowel lengthening procedures or intestinal transplantation, may be considered in refractory cases. Supportive care addresses electrolyte balance, hydration, and prevention of infections. Multidisciplinary care involving gastroenterologists, dietitians, and surgeons is essential. Advances in medical therapy have improved survival and reduced dependence on parenteral nutrition, enhancing long-term outcomes for SBS patients.

Key Questions Answered

• What are the key findings of short bowel syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with short bowel syndrome across the 8 major markets during the forecast period?
• What was the country-wise short bowel syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of short bowel syndrome during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of short bowel syndrome during the forecast period of 2025-2034?
• What are the currently available treatments for short bowel syndrome?
• What are the disease risks, signs, symptoms, and unmet needs of short bowel syndrome?

Scope of the Short Bowel Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of short bowel syndrome based on several factors.
• Short Bowel Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The short bowel syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.